KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Accured Expenses (2016 - 2025)

AbbVie (ABBV) has disclosed Change in Accured Expenses for 14 consecutive years, with -$598.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 147.96% to -$598.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $951.0 million, a 437.29% increase, with the full-year FY2025 number at $951.0 million, up 437.29% from a year prior.
  • Change in Accured Expenses was -$598.0 million for Q4 2025 at AbbVie, down from $1.7 billion in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.5 billion in Q3 2023 to a low of -$1.7 billion in Q2 2024.
  • A 5-year average of $422.8 million and a median of $266.0 million in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 363.89% in 2022, then soared 928.42% in 2023.
  • AbbVie's Change in Accured Expenses stood at $265.0 million in 2021, then surged by 382.26% to $1.3 billion in 2022, then plummeted by 85.99% to $179.0 million in 2023, then skyrocketed by 596.65% to $1.2 billion in 2024, then crashed by 147.96% to -$598.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Change in Accured Expenses are -$598.0 million (Q4 2025), $1.7 billion (Q3 2025), and $515.0 million (Q2 2025).